One of the most surprising conversations I had while working in industry came when a colleague of mine in the regulatory department called to get my input on the value of patient engagement to the company. He was drafting a response to FDA’s proposed...
Who? It’s a big, important story – but it’s easy to get lost in the details. So, let me take a newspaper reporter’s approach here and address essential questions (Who? What? When? Where? Why? How?) about changing relationships between the biopharmaceuticals industry...
Recent Comments